1:1 Bonus Issue: This Small-Cap Pharma Stock Trades Ex-Bonus Tomorrow; Is It in Your Portfolio?

Anuh Pharma Ltd., a small-cap pharmaceutical company, is set to trade ex-bonus on Tuesday, July 15, as it is all set to issue bonus shares in a 1:1 ratio. The company announced the record date last week, which is July 15, and investors who hold the share on or before July 14 will be eligible for the bonus.

Anuh Pharma Bonus Issue Details

In an exchange filing dated July 7th, the company confirmed shareholder approval for issuing a 1:1 bonus.

"This is further to our intimation dated 07th July, 2025. Please note that the Members of the Company have approved the issue of Bonus Shares in the ratio of 1:1, i.e., 1 (one) new fully paid-up Equity Share of ₹ 5/- each for every 1 (one) existing fully paid-up Equity Share of the Company, and that the Bonus Shares so distributed shall, for all purposes, be treated as an increase in the paid-up capital of the Company." the exchange filing read.

Record Date and Ex-Bonus Trading

The record date for determining the eligibility of shareholders for the bonus issue is July 15, 2025. Consequently, Anuh Pharma shares will trade ex-bonus on the same day. Investors looking to be eligible for bonus shares must ensure they purchase the stock before the ex-date, which is Monday, July 14.

Anuh Pharma Share Price Today

Anuh Pharma shares closed at Rs. 208.89 today, marking a gain of Rs. 2.97, or 1.44%, compared to the previous trading session. Over the past five trading days, the stock has declined by 6.43% and 2.26% in the last 30 days of trading, indicating a gradual weakening trend in its price action. Since the beginning of 2025, Anuh Pharma shares have lost 9.58% of their value. Looking at a broader horizon, the stock has dropped 6.26% over the past five years and is currently 40.02% above its 52-week low.

About Anuh Pharma

Anuh Pharma Ltd. is a manufacturer and exporter of Active Pharmaceutical Ingredients (APIs), primarily in the therapeutic categories of macrolide antibiotics, anti-TB, anti-malarial, and anti-inflammatory drugs. The company is part of the SK Group, founded in 1960. The company has a strong presence in both domestic and international markets, exporting its products to over 75 countries, including key markets in Europe, Asia, and Latin America.

The company operates GMP-certified manufacturing facilities and is compliant with several international regulatory standards, including WHO-GMP, EDQM, and KFDA.